At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 218 enrolled
Drug / intervention
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension
In Brief
A Phase 4 clinical trial evaluating Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, and 1 other intervention for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 218 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT® Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedDec 25, 2014
Enrollment StartDec 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.5 years ago
Interventions
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspensiondrug
Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solutiondrug
Subject's habitual PGA monotherapydrug